- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial.
- The new results demonstrate a broad neutralizing antibody response against omicron variants of concern, including BA.5, lasting up to at least six months after administering a low-dose (5 mcg) ARCT-154 booster.
- “Our next generation low-dose self-amplifying (STARR™) mRNA technology continues to differentiate itself from conventional mRNA vaccine technology,” said Joseph Payne, President & CEO.
- “Further validation of the breadth and duration for the immune responses to ARCT-154 are planned in upcoming pivotal clinical trial activities,” he added.
- Related: Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial.
- After one month and three months, neutralizing antibody responses to Omicron BA.5 were 33- and 20-fold elevated over pre-boost responses, respectively.
- After six months, neutralizing antibody responses to omicron BA.1, BA.2, and BA.5 ranged from 22-52 fold, 25-55 fold and 9-24 fold elevated over pre-boost responses, respectively.
- These data show sustained neutralizing responses to antigenically distinct variants of concern, including omicron BA.5, for at least six months after vaccination.
- Price Action: ARCT shares are down 6.79% at $19.05 on the last check Thursday.
Mizuho Maintains Neutral on Fleetcor Technologies, Lowers Price Target to $250
Mizuho analyst Dan Dolev maintains Fleetcor Technologies (NYSE:FLT) with a Neutral and lowers the price target from $275 to $250.
